Ronald Muhlenkamp
Muhlenkamp & Co
Ronald Muhlenkamp SYNERON MEDICAL LTD stake
total: 197
Muhlenkamp & Co ELOS trades
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2015 Q4
- Held for:
- 1 quarter
- Latest activity:
- 2016 Q1
According to 2026 Q2 report, Ronald Muhlenkamp doesn't hold any SYNERON MEDICAL LTD (ELOS) shares. To date, the estimated cost basis is nearly $7.7 for "buy" trades and estimated average "sell" price is $7.7. Muhlenkamp & Co first purchased ELOS in 2015 Q4, initially acquiring 10,255 shares. Since the initial investment in SYNERON MEDICAL LTD (ELOS), Muhlenkamp & Co has made 1 more transaction.
When did Ronald Muhlenkamp sell SYNERON MEDICAL LTD (ELOS)?
Ronald Muhlenkamp sold off the entire SYNERON MEDICAL LTD (ELOS) position in 2016 Q1.
When did Ronald Muhlenkamp buy SYNERON MEDICAL LTD (ELOS)?
Ronald Muhlenkamp first invested in SYNERON MEDICAL LTD (ELOS) in 2015 Q4 at the reported quarter-end price of $7.70 per share.
What's the cost basis of Muhlenkamp & Co's ELOS stake?
The estimated cost basis for SYNERON MEDICAL LTD (ELOS) stake is around $7.70 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $7.70
- Weighted AVG sell price:
- $7.70
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.